Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
5th International Symposium on Hepatitis Care in Substance Users
Wednesday 7 September - Friday 9 September 2016 • Oslo, Norway
INHSU 2016Conference Handbook
@INHepSU • #INHSU16 • inhsu2016.com
Published in 2016 by the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
National Office: Locked Mail Bag 5057 Darlinghurst NSW 1300, Australia
T +61 2 8204 0770 F +61 2 8204 0779 E [email protected] W www.ashm.org.au
ABN: 48 264 545 457 CFN: 17788
© ASHM 2016 Design and layout by Steph Yamey
Printed by Just Cruzin' Production
INHSU 2016 - Conference Handbook 1
CONTENTS
CONFERENCE ENVIRONMENT POLICY
ASHM Conference and Events Division implements a waste-reduction policy that addresses:
� Reduce, Reuse, Recycle. This is done before, during and after each conference.
� ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
� ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
� ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
� ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
� ASHM Conference & Events Division will endeavour to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.
ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.
Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Poster Listings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Venue Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Location Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Social Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Industry Sponsored Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Exhibition Booth Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2
WELCOME
Welcome to Oslo!
Dear delegate at INHSU 2016
We want to welcome you to Oslo and the 5th International Symposium on Hepatitis Care in Substance Users 7 - 9 September, 2016. We have a very exciting programme for you.
Hepatitis C is a main health problem among people who inject drugs. We do have effective drugs against hep C available today, but only a small minority of those who use drugs actually have access to them. This has to change! We therefore think the conference should discuss the following issues: 1) HCV epidemiology, screening, assessment; 2) HCV treatment and care; and 3) HCV treatment access and implementation. A new feature of this year’s conference is the workshops which will bring together health professionals, researchers, community organisations, people who use drugs and policy makers. We hope this will facilitate change in the field of hepatitis C in people who use drugs.
INHSU 2016 is organized by the International Network on Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. INHSU 2016 is sponsored by AbbVie, Bristol Myers Squibb, Gilead, Janssen, MSD, Open Society Foundations, Akershus University Hospital and The Norwegian Research Fund.
We hope that you enjoy the conference as well as the pleasures that Oslo and its surrounding areas have to offer.
Regards,
Professor Olav Dalgard, Akershus University Hospital Conference Chair
INHSU 2016 - Conference Handbook 3
The 2016 INHSU Committee would like to thank all the sponsors, supporters, presenters and participants who helped bring this Conference together.
On behalf of the Organising Committee:
OLAV DALGARD Akershus University Hospital, Norway
HÅVARD MIDGARD Akershus University Hospital, Norway
JASON GREBELY The Kirby Institute, UNSW, Australia
Local Scandinavian Committee:
KJERSTI ULSTEIN HCV Clinic, Oslo, Norway
ØYSTEIN BACKE HCV Clinic, Oslo, Norway
KRISTIN VENNESLAND HCV Clinic, Oslo, Norway
KNUT BOE KIELLAND Innlandet Hospital Trust, Norway
RONNY BJØRNESTAD ProLAR, Norway
BENT ARILD STORNES ProLAR, Norway
PEER BREHM CHRISTENSEN University of Southern Denmark, Denmark
ANNE ØVREHUS University of Southern Denmark, Denmark
MARTIN KÅBERG Karolinska Institutet, Sweden
AMY SARGENT Project Officer, ASHM Conference & Events Division, Australia
NADINE GIATRAS Division Manager, ASHM Conference & Events Division, Australia
4
GENERAL INFORMATION
CONFERENCE VENUE
Holbergsgate 300166 Oslo, NorwayTel: +47 23 29 30 00 • Fax: +47 23 29 30 01Email: [email protected]
REGISTRATION DESK
Foyer, Radisson Blu Scandinavia Hotel
The INHSU conference registration will be open from 8.00am, Wednesday 7 September 2016.
NAME BADGES
For security purposes all attendees must wear their name badge at all times whilst in the Radisson Blu Scandinavia Hotel. If you misplace your name badge, please advise staff at the Registration Desk.
INTERNET AREA
An Internet area is available for the duration of the meeting in the Foyer, Radisson Blu Scandinavia Hotel.
The internet hub and wireless internet access for the INHSU Conference has been proudly sponsored by MSD.
CATERING
Morning and afternoon tea breaks will be served in the Exhibition Area in the Foyer. Lunch will be served in Holberg Restaurant. The conference catering has been proudly sponsored by Abbvie
JUICE BAR
A Juice Bar will be available to delegates during morning and afternoon tea breaks and served in the Exhibition area. The Juice Bar has been proudly sponsored by Janssen.
SPEAKER PREPARATION DESK
The speaker preparation room will be located in the Asker room.
All speakers must take their presentation to the speaker preparation desk a minimum of four hours prior to their presentation or the day before if presenting at a morning session.
MOBILE PHONES/BEEPERS
As a courtesy to all delegates and speakers, please switch off, or set to silent, your mobile phones and beepers during all sessions.
PERSONAL MAILThe conference organisers do not accept responsibility for personal mail. Please have all mail sent to your accommodation address.
SMOKING This conference has a no smoking policy.
POSTER DISPLAYS
Posters will be displayed for the duration of the conference, these are located in the Helsingfors room.
WI-FI INTERNET Username: INHSU • Password: INHSU2016
PARKINGCar parking is available in the hotel garage for an extra charge. All parking is subject to availability.
INHSU 2016 - Conference Handbook 5
PROGRAMME: Wednesday 7 September
EPIDEMIOLOGY AND PUBLIC HEALTH
8.00am Registration: Foyer
9.00am - 9.15am
Opening Ceremony
Room: Scandinavia Ballroom
9.00am - 9.10am
Welcome to the Conference Olav Dalgard, Akershus University Hospital, Norway
9.10am - 9.15am
Opening from Community Member Ronny Bjørnestad, proLAR, Norway
9.15am - 10.40am
Session A: HCV Epidemiology
Room: Scandinavia BallroomChairs: Tom Hemming Karlsen, University of Oslo and Magdalena Harris, London School of Hygeine and Tropical Medicine, United Kingdom
9.15am - 9.35am
The Burden of HCV Infection among PWID Sharon Hutchinson, Glasgow Caledonian University, United Kingdom
9.35am - 9.55am
The Natural History of HCV Infection Knut Boe Kielland, Innlandet Hospital Trust, Norway
9.55am - 10.10am
Can Health Risk Behaviours Explain the High Mortality Rate for Adults with Chronic Hepatitis C in the United States? Hamish Innes, Glasgow Caledonian University, United Kingdom
10.10am - 10.25am
Effect of Combined Harm Reduction Strategies on HCV Primary and Reinfection Incidences among People Who Inject Drugs in Montreal, CanadaJulie Bruneau, Université de Montréal, Canada
10.25am - 10.40am
The Prison Economy of Needles and Syringes: What Opportunities Exist for Hepatitis C Risk Reduction When Prices are so High?Carla Treloar, Centre for Social Research in Health, University of New South Wales, Australia
10.40am - 11.00am
Coffee Break in Foyer
11.00am - 12.00pm
Session B: Harm Reduction
Room: Scandinavia BallroomChairs: Matt Hickman, University of Bristol, United Kingdom and Ronny Bjørnestad, proLAR, Norway
11.00am - 11.20am
State-of-the-Art Lecture: Opioid and Stimulant Substitution TreatmentJohan Franck, Karolinska Institutet, Sweden
11.20am - 11.40am
Sharing of Needles, Syringes and Injecting Equipment: Risk of HCV Transmission and Prevention Potential Holly Hagan, New York University, United States of America
11.40am - 12.00pm
Advances and Opportunities for Harm Reduction in Europe Mags Maher, EuroNPUD, United Kingdom
GENERAL INFORMATION
6
EPIDEMIOLOGY AND PUBLIC HEALTH
12.00pm - 1.45pm
Lunch in Restaurant
12.15pm - 1.15pm
Industry Sponsored Symposium: A Practical Approach to Treating HCV in PWID Room: Stockholm/Oslo
1.45pm - 3.00pm
Session C: Oral Abstracts Epidemiology and Public Health
1.45pm - 3.00pm
Session D: Oral Abstracts Epidemiology and Public Health
Room: København Chairs: Peter Vickerman, University of Bristol, United Kingdom and Angella Duvnjak, Australian Injecting & Illicit Drug Users League, Australia
Room: Stockholm/OsloChairs: Lisa Maher, The Kirby Institute, University of New South Wales, Australia and Chloé Forette, Médecins du Monde, France
1.45pm - 2.00pm
Hepatitis C and HIV Treatment Cascades among People Who Inject Drugs. Results from a Sero-Behavioural Survey among Current Injectors in GermanyRuth Zimmermann, Robert Koch Institute, Germany
1.45pm - 2.00pm
Molecular Epidemiology of Full-Length Hepatitis C Virus Genomes among Injecting Drug Users with Recent Infection: The Inc3 StudyChaturaka Rodrigo, University of New South Wales, Australia
2.00pm - 2.15pm
The Role of Incarceration in HCV Transmission amongst People who Inject Drugs: A Modelling AnalysisJack Stone, University of Bristol, United Kingdom
2.00pm - 2.15pm
Liver Disease Burden and Clinical Follow-Up during a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The Liverlife StudyJason Grebely, Kirby Institute, University of New South Wales, Australia
2.15pm - 2.30pm
Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting: The HITS-P StudyEvan Cunningham, University of New South Wales, Australia
2.15pm - 2.30pm
Successful Model of Testing and Linking People who Inject Drugs (PWID) to Treatment using Direct Acting Antivirals Nalinikanta Rajkumar, Community Network for Empowerment (CoNE), India
2.30pm - 2.45pm
Network-Based Modeling for HCV in US Drug Injectors: Treatment as PreventionAlexei Zelenev, Yale School of Medicine, United States of America
2.30pm - 2.45pm
Changes in Risk Behaviours during and Following Treatment for Hepatitis C Virus Infection among People Who Inject Drugs: The ACTIVATE StudyHåvard Midgard, Akershus University Hospital, Norway
PROGRAMME: Wednesday 7 September
INHSU 2016 - Conference Handbook 7
EPIDEMIOLOGY AND PUBLIC HEALTH
2.45pm - 2.50pm
Monitoring HCV among People Who Inject Drugs in Europe: A Set of Indicators to Serve Policy and PracticeIsabelle Giraudon, European Monitoring Centre for Drugs and Drug Addiction, Portugal
2.45pm - 2.50pm
Exposure to opioid substitution therapy following hepatitis C notification: Implications for provision of antiviral therapies in drug treatment settingsSarah Larney, National Drug and Alcohol Research Centre, University of New South Wales, Australia
2.50pm - 2.55pm
Combining the Expansion of Medicated Assisted Therapies and HCV Treatment among PWID in Ukraine: Insights from Network ModelingAlexei Zelenev, Yale School of Medicine, United States of America
2.50pm - 2.55pm
Fatigue in Patients with Chronic Hepatitis C: The FAT-HEP Study. A Cross Sectional Study of Fatigue and its Relation to Substance Use and OSTsAnne Øvrehus, MD, University of Southern Denmark, Denmark
2.55pm - 3.00pm
HCV Infection and HIV-HCV Coinfection among “New” Injectors during an HIV Outbreak in Athens, Greece: Results from the Aristotle ProgrammeVana Sypsa, National and Kapodestrian University of Athens, Greece
2.55pm - 3.00pm
Multi-Disciplinary Managed Care Networks-Lifesaving Interventions for Hepatitis C PatientsJohn Dillon, University of Dundee, United Kingdom
3.00pm - 3.30pm
Coffee Break in Foyer
3.30pm - 3.45pm
Poster Highlights Room: Scandinavia Ballroom Chair: Jason Grebely, The Kirby Institute, University of New South Wales, Australia
3.45pm - 5.00pm
Session E: Limiting the HCV Epidemic
Room: Scandinavia BallroomChairs: Kimberly Page, University of New Mexico Health Sciences Center, United States of America and Berne Stålenkrantz, The Swedish Drug Users Union, Sweden
3.45pm - 4.05pm
State-of-the-Art Lecture: HCV Treatment as Prevention Matthew Hickman, University of Bristol, United Kingdom
4.05pm - 4.25pm
HCV Vaccine Development: Where Do We Stand? Andrea Cox, John Hopkins University, United States of America
4.25pm - 4.45pm
The Ebola Vaccine Experience: Cluster Randomisation and Implications for HCV Trial Design John-Arne Røttingen, Norwegian Institute of Public Health, Norway
4.45pm - 5.00pm
Liver Or Die: A Peer Training Manual Berne Stålenkrantz, The Swedish Drug Users Union, Sweden
5.00pm - 6.30pm
Welcome Reception & Poster Viewing Session in Foyer
8
PROGRAMME: Thursday 8 September
TREATMENT AND CARE
9.00am - 10.30am
Session F: HCV Treatment Among PWID
Room: Scandinavia BallroomChairs: Julie Bruneau, Université de Montréal, Canada and Margaret Maher, EuroNPUD, United Kingdom
9.00am - 9.20am
State-of-the-Art Lecture: Treatment of HCV Infection in 2016 Graham Foster, University of London, United Kingdom
9.20am - 9.40am
HCV Treatment Trials among PWID Gregory Dore, The Kirby Institute, University of New South Wales, Australia
9.40am - 9.55am
Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine Sergii Filippovych, International Charitable Foundation “Alliance for Public Health”, Ukraine
9.55am - 10.10am
C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons Who Inject Drugs Receiving Opioid Agonist TherapyOlav Dalgard, Akershus University Hospital, Norway
10.10am - 10.25am
“I got my life back!” - Patients’ experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients. Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital, Denmark
10.25am - 11.00am
Coffee Break in Foyer
11.00am - 12.00pm
Session G: Living with HCV Infection
Room: Scandinavia BallroomChairs: Philip Bruggmann, Arud Zentren Für Suchtmedizin, Switzerland and Jude Byrne, Australian Injecting & Illicit Drug Users League, Australia
11.00am - 11.10am
Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue? Olav Dalgard, Akershus University Hospital, Norway
11.10am - 11.20am
The Patient Perspective Andi Hüttenmoser, Switzerland
11.20am - 11.30am
“But a spoon is not equipment”: Risk Behaviour and Knowledge Seeking among HCV-infected PWID Alexandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences
11.30am - 12.00pm
Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use? Moderator: Graham Foster, University of London, United Kingdom Anne Øvrehus, University of Southern Denmark, DenmarkMartin Kåberg, Karolinska Institutet, SwedenSharon Hutchinson, Glasgow Caledonian University, United KingdomPeer Brehm Christensen, University of Southern Denmark, Denmark
12.00pm - 1.45pm
Lunch in Restaurant
12.15pm - 1.15pm
Industry Sponsored Symposium: Making HCV Elimination a Reality for PWID Room: Stockholm/Oslo
INHSU 2016 - Conference Handbook 9
TREATMENT AND CARE
9.00am - 10.30am
Session F: HCV Treatment Among PWID
Room: Scandinavia BallroomChairs: Julie Bruneau, Université de Montréal, Canada and Margaret Maher, EuroNPUD, United Kingdom
9.00am - 9.20am
State-of-the-Art Lecture: Treatment of HCV Infection in 2016 Graham Foster, University of London, United Kingdom
9.20am - 9.40am
HCV Treatment Trials among PWID Gregory Dore, The Kirby Institute, University of New South Wales, Australia
9.40am - 9.55am
Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine Sergii Filippovych, International Charitable Foundation “Alliance for Public Health”, Ukraine
9.55am - 10.10am
C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons Who Inject Drugs Receiving Opioid Agonist TherapyOlav Dalgard, Akershus University Hospital, Norway
10.10am - 10.25am
“I got my life back!” - Patients’ experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients. Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital, Denmark
10.25am - 11.00am
Coffee Break in Foyer
11.00am - 12.00pm
Session G: Living with HCV Infection
Room: Scandinavia BallroomChairs: Philip Bruggmann, Arud Zentren Für Suchtmedizin, Switzerland and Jude Byrne, Australian Injecting & Illicit Drug Users League, Australia
11.00am - 11.10am
Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue? Olav Dalgard, Akershus University Hospital, Norway
11.10am - 11.20am
The Patient Perspective Andi Hüttenmoser, Switzerland
11.20am - 11.30am
“But a spoon is not equipment”: Risk Behaviour and Knowledge Seeking among HCV-infected PWID Alexandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences
11.30am - 12.00pm
Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use? Moderator: Graham Foster, University of London, United Kingdom Anne Øvrehus, University of Southern Denmark, DenmarkMartin Kåberg, Karolinska Institutet, SwedenSharon Hutchinson, Glasgow Caledonian University, United KingdomPeer Brehm Christensen, University of Southern Denmark, Denmark
12.00pm - 1.45pm
Lunch in Restaurant
12.15pm - 1.15pm
Industry Sponsored Symposium: Making HCV Elimination a Reality for PWID Room: Stockholm/Oslo
TREATMENT AND CARE
1.45pm - 3.00pm
Session H: Oral Abstracts Clinical
1.45pm - 3.00pm
Session I: Oral Abstracts Social Sciences and Community
Room: KøbenhavnChairs: Brian Conway, Vancouver ID Centre, Canada and Georgios Zarkotos, Greek Drug Users Union, Greece
Room: Stockholm/Oslo Chairs: Carla Treloar, Centre for Social Research in Health, Univeristy of New South Wales, Australia
1.45pm - 2.00pm
Outreach Screening and Treatment for Hepatitis C in a Drug Treatment Unit – An Exploratory Assessment of Feasibility and Cost EffectivenessAshley Brown, St Mary’s Hospital, United Kingdom
1.45pm - 2.00pm
Relationships and Injecting Dyads: Identifying Key Interpersonal Factors Underlying Injecting Behaviors and Hepatitis C Virus (HCV) Transmission among Injecting PartnershipsMeghan Morris, University of California, San Francisco, United States of America
2.00pm - 2.15pm
High Rates of Sustained Virological Response in People Who Inject Drugs Treated with All-Oral Direct Acting Antiviral RegimensAlain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center, United States of America
2.00pm - 2.15pm
Becoming a Buddy: Accordance and Incompatibility in the Hepatitis C Peer Support RoleMagdalena Harris, London School of Hygiene and Tropical Medicine, United States of America
2.15pm - 2.30pm
Real World Outcomes of Direct Acting Antiviral (DAA) Therapy for Hepatitis C (HCV) Amongst Persons Who Inject Drugs Treated in an Inner-city Hepatitis C treatment Program, Vancouver, CanadaMark Hull, BC Centre for Excellence in HIV/AIDS, Canada
2.15pm - 2.30pm
Qualitative Evaluation of the Decisions and Experiences of People who Inject Drugs who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife StudyAlison Marshall, The Kirby Institute University of New South Wales, Australia
2.30pm - 2.45pm
Comparison of Rates of Recurrent HCV Viremia in High-Risk Patients Receiving All-Oral and Interferon-Based RegimensTyler Raycraft, Vancouver ID Research and Care Centre Society, Canada
2.30pm - 2.45pm
Qualitative Insights into the Lived Experience of Interferon-Free TreatmentsDavid Whiteley, Edinburgh Napier University, United Kingdom
2.45pm - 2.50pm
Treatment Evaluation and Uptake among Persons with Chronic Hepatitis C on Opium Substitution Therapy. Is Treatment as Prevention Realistic?Anne Øvrehus, Odense University Hospital, Denmark
2.45pm - 2.50pm
The Australian Response and Uptake of the New Subsidised Hepatitis C Direct Acting Anti-Virals among the Community of People Who Inject DrugsJude Byrne, The Australian Injecting and Illicit Drug users League, Australia
10
TREATMENT AND CARE
2.50pm - 2.55pm
Optimal Adherence during HCV Treatment amongst Active Drug Users at a Community Based Program in Toronto, CanadaKate Mason, South Riverdale Community Health Centre, Canada
2.50pm - 2.55pm
Blood Borne Virus Risk Behaviours among People Who Inject Drugs in the UK: A Qualitative ExplorationDavina Swan, King’s College London, United Kingdom
2.55pm - 3.00pm
Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot StudyBrianna Norton, Division of Internal Medicine, Montefiore Medical Center, United States of America
2.55pm - 3.00pm
Utilising Social Capital to Promote HCV Treatment in PrisonLise Lafferty, The Kirby Institute, University of New South Wales, Australia
3.00pm - 3.30pm
Coffee Break in Foyer
3.30pm - 5.00pm
Session J: Assessment and Management of HCV Infection
Room: Scandinavia BallroomChairs: Jason Grebely, Kirby Institute, University of New South Wales, Australia and Kanta Rajkumar, CONE, India
3.30pm - 3.50pm
Simplified HCV Diagnostics Teri Roberts, MSF Access Campaign, Switzerland
3.50pm - 4.00pm
It’s Your Liver: Peer to Peer HCV Testing and Education Bent Arild Stornes, ProLAR, Norway
4.00pm - 4.20pm
Liver Disease Assessment among PWID: The Role of Transient Elastography Peer Brehm Christensen, University of Southern Denmark, Denmark
4.20pm - 4.40pm
HCV Reinfection Following Successful Treatment: Clinical and Public Health Implications Håvard Midgard, Akershus University Hospital, Norway
4.40pm - 5.00pm
Understanding Liver Cirrhosis and its Complications John Willy Haukeland, Oslo University Hospital, Norway
5.00pm - 6.00pm
INHSU General Assembly Members Meeting
7.00pm - 11.00pm
Conference Dinner at Posthallen
PROGRAMME: Thursday 8 September
INHSU 2016 - Conference Handbook 11
PROGRAMME: Friday 9 September
ACCESS AND IMPLEMENTATION
Session K: Parallel Workshops
8.30am - 10.00am
Workshop #1: Getting Involved: Peer SupportLocation: HelsingforsChair: Berne Stålenkrantz, The Swedish Drug Users Union, Sweden
Workshop #2: HCV Prevention: What Works and What Doesn’t?Location: KøbenhavnChair: Holly Hagan, New York University, United States of America and Eberhard Schatz, Correlation Network, Netherlands
Workshop #3: HCV Testing and Care in PrisonsLocation: StockholmChair: Andrew Lloyd, University of New South Wales, Australia and Pernille Sauer, Aarhus University Hospital, Denmark
Workshop #4: Liver Disease Assessment among PWID: Hands OnLocation: OsloChairs: Peer Brehm Christensen, University of Southern Denmark, Denmark; Håvard Midgard, Akershus University Hospital, Norway
Workshop #5: The Low Threshold HCV ClinicLocation: SkagerakChair: John F Dillon, University of Dundee, United Kingdom and Leon Wylie, Hepatitis Scotland, United Kingdom
Workshop #6: HCV Epidemiology: Populations, Data Sources and Missing DataLocation: EidsvollChair: Matthew Hickman, University of Bristol, United Kingdom, Greg Dore, The Kirby Institute, University of New South Wales, Australia and Julie Bruneau, Université de Montréal, Canada
10.00am - 10.45am
Coffee Break in Foyer
10.45am - 12.00pm
Session L: Novel Models of HCV Care
Room: Scandinavia BallroomChairs: Greg Dore, The Kirby Institute, University of New South Wales, Australia and Mary Harrod, New South Wales Users & AIDS Association, Australia
10.45am - 11.05am
HCV Treatment in the Prison Setting Andrew Lloyd, University of New South Wales, Australia
11.05am - 11.25am
Pharmacy Based HCV Treatment John F Dillon, University of Dundee, United Kingdom
11.25am - 11.40am
Decentralised HCV Shared Care: The SACC Project Lars Peters, Rigshospitalet, Denmark
11.40am - 12.00pm
New Technologies for Addressing Treatment Barriers and Treatment AdherenceJeffrey J Weiss, Mount Sinai Hospital, United States of America
12.00pm - 1.45pm
Lunch in Restaurant
12.15pm - 1.15pm
Industry Sponsored Symposium: TREAT TO CURE. TREAT TO PREVENT:Management of Substance Users with HCV Infection Room: Scandinavia Ballroom
12
ACCESS AND IMPLEMENTATION
1.45pm - 2.45pm
Session M: Drug Policy
Room: Scandinavia BallroomChairs: Margaret Hellard, Burnet Institute, Australia and Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia
1.45pm - 2.05pm
War on Drugs or War on Disease? Ethan Nadelmann, Drug Policy Alliance, United States of America
2.05pm - 2.25pm
Report from United Nations General Assembly Special Session on the World Drug Problem 2016 Daniel Wolfe, Open Society Foundations, United States of America
2.25pm - 2.30pm
HA-REACT: The European Joint Action on HIV and Coinfection Prevention and Harm Reduction - What’s in it for Hepatitis? Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark
2.30pm - 2.50pm
Can information and communication technologies (ICTs) increase treatment opportunities for people who are homeless and people who inject drugs? Jo Neale, King’s College London, United Kingdom
2.50pm - 3.00pm
The INHSU Video Project Nikki Cavenagh, The Digital Clinic, Australia
3.00pm - 3.15pm
Coffee Break in Foyer
3.15pm - 4.00pm
Session N: HCV Care in Resource-Limited Countries
Room: Scandinavia BallroomChairs: Jeff Lazarus, Rigshospitalet, University of Copenhagen, Denmark and Janko Belin, Društvo AREAL, Slovenia
3.15pm - 3.35pm
The Georgia HCV Elimination Program Maia Butsashvili, Health Research Union, Georgia
3.35pm - 3.55pm
Russia: Hepatitis C Treatment Gap and Ways Forward Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia
3.55pm - 4.15pm
Access to DAAs from an Asian Perspective Giten Khwairakpam, TREAT Asia, Thailand
4.15pm - 4.25pm
HCV Infection among PWID: Research Priorities for Optimizing Prevention, Management and Treatment in the Era of DAAs Jason Grebely, The Kirby Institute, University of New South Wales, Australia
4.25pm - 4.30pm
Conference Closing in Scandinavia Ballroom
PROGRAMME: Friday 9 September
INHSU 2016 - Conference Handbook 13
POSTER LISTINGPosters will be displayed in Helsingfors Room
# TITLE OF ABSTRACT PRESENTER
01Addressing HIV/HCV Co-Infection among Injecting Drug Users in Jakarta, Indonesia using Peer Driven Intervention
EDO AGUSTIAN
02Circumstances around First Drug Injection and Prevalence of HIV, Hepatitis B (HBV) and Hepatitis C (HCV) Among Participants of a Needle Exchange Program (NEP)
MARIANNE ALANKO BLOMÉ
03Cause-Specific Mortality among People with a Hepatitis C Notification: A Population-Based Linkage Study, 1993- 2012
MARYAM ALAVI
04Reduced HCV Recurrent Viremia in PWID with Treatment Induced Virologic Clearance through a Comprehensive Multidisciplinary Treatment Model
ARSHIA ALIMOHAMMADI
05Hepatitis B Virus (HBV) Serological Status among People Who Enter the Opioid Substitution Programme in Greece
OLGA ANAGNOSTOU
06Incidence and Predictors of Hepatitis C Treatment Initiation among People who Inject Drugs: Longitudinal Data from a Greek Tertiary Center, 2009-2015.
OLGA ANAGNOSTOU
07Low-Threshold Hepatitis C Treatment for People Who Inject Drug – How to Ensure Compliance and Treatment Success
ØYSTEIN BACKE / KRISTIN VENNESLAND
08Modelling Hepatitis C Virus Transmission in a High-Risk Incarcerated Population
NEIL BRETANA
09HCV Treatment Initiation among HCV Infected PWID in Capica, A Retrospective Study in Twelve Canadian Clinical Settings
JULIE BRUNEAU
10Heroin Assisted Treatment Setting: Feasibility and Efficacy of Hepatitis C DAA Treatment
NATHALIE BRUNNER
11Hepatitis C Testing in the General Practice Setting for Australians Who Inject Drugs
KERRYN BUTLER
12 Hepatitis C Virus RNA Quantification on Dry Capillary Blood Spot ERIKA CASTRO
13 DAA 2nd Generation Treatment Outcome in Substance Users ERIKA CASTRO
14Attitudes towards Hepatitis C and Treatment Willingness among People Who Inject Drugs: A Follow- Up Interview Study
DISA DAHLMAN
15Stage of Liver Disease in Hepatitis C Patients at a Low- Threshold Hepatitis C Clinic in Oslo
OLAV DALGARD
16High Hepatitis C Virus Reinfection Rate after Achieving Sustained Virological Response (Svr) among People who Inject Drugs Actively: Tactic Cohort
LUCIE DESHAIES
14
# TITLE OF ABSTRACT PRESENTER
17Trends In Hepatocellular Carcinoma Among People Receiving Opioid Substitution Therapy With an HCV Notification In New South Wales, Australia Between 2000 and 2014
GREG DORE
18Baseline Characteristics and Recruitment in a Randomised Trial of Community Vs Hospital Direct Acting Antiviral Treatment for Hepatitis C
JOSEPH DOYLE
19Eliminating Hepatitis C Transmission by Enhancing Care and Treatment among HIV Co-Infected Individuals: The Co-EC Study
JOSEPH DOYLE
20Experiences of alcohol use and hepatitis c among people who inject drugs: implications for treatment services.
JANE EVELY
21 HCV Capacity Building Trainings for Harm Reduction and Peer Workers JASON FARRELL
22High Rates of Sustained Virological Response in People Who Inject Drugs Treated With Sofosbuvir-Based Regimens in Ukraine
SERGII FILIPPOVYCH
23Intermittent Injecting Drug Use and HCV Incidence in an Observational Cohort Study of People Who Inject Drugs in Montréal, Canada
EMMANUEL FORTIER
24Scaling Up HCV Treatment, Syringe Services and Medicated-Assisted Treatment for Achieving Rapid HCV Elimination in Rural America – Model Projections For Indiana
HANNAH FRASER
25Real World Experience in HCV Awareness, Testing, Care and Knowledge Transfer in La Ronge, Saskatchewan
LESLEY GALLAGHER
26Past Incarceration Experience and the Risk of Hepatitis C Infection among People Who Inject Drugs: Results from a Sero-Behavioral Survey among Current Injectors in Germany
MARTYNA GASSOWSKI
27Efficacy of Sofosbuvir/Ledipasvir With and Without Ribavirin in Patients with Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
JASON GREBELY
28Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
JASON GREBELY
29 Efficacy of All-Oral HCV Therapy in People who Inject Drugs SYUNE HAKOBYAN
30Portable Pop-Up Clinics: Characteristics of Engagement in Care, an Observational Prospective Cohort Study
SYUNE HAKOBYAN
31Analysis of Adherence to All-Oral HCV Therapy in a Cohort of People Who Inject Drugs (PWID)
SYUNE HAKOBYAN
32
Direct observed therapy of Chronic Hepatitis C with Interferon-Free All-Oral regimens at a Low-Threshold Drug Treatment facility – A new concept for treatment of patients with Borderline Compliance receiving Opioid Substitution Therapy
HANS HALTMAYER
POSTER LISTING
INHSU 2016 - Conference Handbook 15
# TITLE OF ABSTRACT PRESENTER
33Peer Support for People Living with Hepatitis C in Drug and Alcohol Settings Increases Hep C Assessment and Knowledge
MARY HARROD
34Ethical Research and Engagement with People Who Use Drugs: Frameworks and Implementation
MARY HARROD
35Geographic Determinants of Hepatitis C Screening in a Mixed Urban/Rural Epidemic
KARLI HOCHSTATTER
36Hepatitis C Testing and Undiagnosed Infections among People Injecting Image and Performance Enhancing Drugs in England & Wales: 2012-15
VIVIAN HOPE
37Factors Associated with Entry into Healthcare Pathways for Hepatitis C among People who Inject Psychoactive Drugs in the United Kingdom (UK)
VIVIAN HOPE
38Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia
JENNY IVERSEN
39Infcare Needle Syringe Program (Infcare NSP), A Database for following and Reducing Injection Risk Behavior Over Time in PWID in Stockholm
MARTIN KÅBERG
40Pre-Testing Knowledge of Hepatitis C Status among 1504 Consecutive Participants at the Stockholm Needle Exchange
MARTIN KÅBERG
41 Does Chronic Hepatitis C Cause Fatigue? KNUT BOE KIELLAND
42 Injecting Drug Use Among Inmate in Norwegian Prisons KNUT BOE KIELLAND
43Aggressive Treatment of Hepatitis C in People Who Inject Drugs in Norway: An Integral Step to Eradicate the Infection in this Population
KNUT BOE KIELLAND
44The Hep-NORDIC project: viral hepatitis c management policies for people who inject drugs in the five Nordic countries
JEFFREY LAZARUS
45Modelling the Impact of Interventions Targeting High- Risk Populations on the HCV Epidemic in Pakistan
AARON LIM
46Impact of HCV Advocacy and Demonstration Treatment Programs Specifically Targeted at PWIDS on National Hepatitis Policy
LUDMILA MAISTAT
47A Qualitative Study of the Perceptions of Interferon- Free Therapy for Hepatitis C Virus Infection among People Who Inject Drugs: The Liver life Study
ALISON MARSHALL
48Substantial Decline of Hepatitis C Virus Prevalence among PWID in Flanders, Belgium: The Result of a Comprehensive Approach
CATHARINA MATHEÏ
49 Earth Study (Phase 1): Expanding Access to Rapid Treatment for Hep C DEE MENEZES
50Reinfection of Hepatitis C among People Who Inject Drugs in Norway: Opportunity for Intervention-A Modelling Study
HAVARD MIDGARD
16
POSTER LISTING
# TITLE OF ABSTRACT PRESENTER
51Improved Access to HCV Treatment for Substance Users: The Impact of On-Site Transient Elastography in an Inner City Community Health Centre
ROZALYN MILNE
52Prospective Data on People Who Use Drugs in Switzerland: The SAMMSU Cohort
ALBERTO MORIGGIA
53High Prevalence of Liver Fibrosis among People Attending Addiction Clinics and Rehabilitation Facilities in Southern Switzerland: Results of Two Different Screening Programs for Liver Disease
ALBERTO MORIGGIA
54Development and Validation of a Novel Measurement Scale for Interpersonal Factors Underlying Injection Drug Using Behaviors
MEGHAN MORRIS
55Dried Blood Spot, Valid Screening Method for Viral Hepatitis and HIV in Real-Life
BELINDA KLEMMENSEN MÖSSNER
56Low Levels of HCV Awareness and Risk Among Groups Most at Risk in Vietnam
HUONG NGO
57Concordance between Self-Reported and Measured HIV and Hepatitis C Virus Infection Status among People Who Inject Drugs in Germany
STINE NIELSEN
58Are There Missed Opportunities for Vaccinating Against Hepatitis B among People Who Inject Drugs (PWID) In The United Kingdom (UK)?
JACQUELYN NJOROGE
59Dot-C: A Pilot Trial of Directly Observed Anti HCV Therapy in a Population Receiving Opiate Substitution Therapy (OST) from a Pharmacy - Uptake of Testing Results
ANDREW RADLEY
60Adherence to Hepatitis C Treatment Regimen among People Who Inject Drugs in Norway: Implications for Treatment Strategies
DEVIN RAZAVI-SHEARER
61Compass Project, Inside and Outside Link for Prisoners and PWID with Hepatitis C in France
ANDRE JEAN REMY
62Global Genotype Distribution of Hepatitis C Viral Infection among People who Inject Drugs
GEERT ROBAEYS
63Hepatitis C Treatment on PWUD in the DAA’S Era: High Rate of Virological Response in the Real Life
ANTONELLA ROBATTO
64Trends of Hepatitis C Virus Epidemic in Australia and North America in 20th Century: Back Projections from Molecular Epidemiology
CHATURAKA RODRIGO
65Drug Market Variations and Drug Use Practices among People Who Inject Drugs in the Province of Québec, Canada
ÉLISE ROY
66Hepatitis C and Risk Behavior among Persons Who Inject Drugs in Norway
RIKARD RYKKVIN
INHSU 2016 - Conference Handbook 17
# TITLE OF ABSTRACT PRESENTER
67The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk Behaviours among People Who Inject Drugs: A Systematic Review and Meta-Analysis
DAVINA SWAN
68Training Drug Users in Overdose Reversal with Intranasal Naloxone – A New Approach to Address Opioid Overdoses and other General Health Problems
HENRIK THIESEN
69The Effects of Alcohol on Spontaneous Clearance of Acute Hepatitis C Virus Infection in Females versus Males Who Inject Drugs
JUDITH TSUI
70Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Infection in a Low Threshold Setting
KJERSTI ULSTEIN
71Prevalence and Determinants of Liver Disease among People who use Drugs in Amsterdam, The Netherlands
DANIELA VAN SANTEN
72From the Users’ Perspective – An Interview Study with People who Inject Drugs on the Usefulness of Participating in a Needle Syringe Program
MALIN VÄRMÅ FALK
73Impact of Current and Scaled Up Levels of Needle and Syringe Programmes and Opiate Substitution Therapy in Three UK Settings
ZOE WARD
74C-Buddies: Missing Piece of the Puzzle in a Comprehensive “Not Under One Roof“. Approach for Hepatitis C Management Among People Who Use Drugs
TESSA WINDELINCKX
75Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic
VICCI GOODWIN
a Estimates are based on peginterferon + ribavirin treatment era and some date back to 2008.1,2
1. Grebely J, Dore GJ. Antiviral Res 2014;104:62–72. 2. European Centre for Disease Prevention and Control, 2015. Hepatitis C surveillance in Europe – 2013. Stockholm: ECDC. Available from http://ecdc.europa.eu/en/publications/Publications/hepatitis-c-surveillance-in-europe-2013.pdf. Accessed July 2016. 3. Perlman DC et al. Int J Drug Policy 2015;26:1056–1063.
© 2016 Gilead Sciences Europe Limited HCV/IHQ/16-07//1999 Date of preparation: July 2016
67% OF PEOPLE WHO INJECT DRUGS
HAVE HEPATITIS C, GLOBALLY1
10 MILLIONPEOPLE WHO INJECT
DRUGS IN THE WORLD HAVE HEPATITIS C1
~80% OF NEW HEPATITIS C INFECTIONS RESULT
FROM INJECTION DRUG USE2
~90% OF HEPATITIS C
PATIENTS WHO INJECT DRUGS FAIL TO INITIATE
HEPATITIS C TREATMENT1,3,a
SCREEN DIAGNOSE REFERYou are the first step towards cure
a Estimates are based on peginterferon + ribavirin treatment era and some date back to 2008.1,2
1. Grebely J, Dore GJ. Antiviral Res 2014;104:62–72. 2. European Centre for Disease Prevention and Control, 2015. Hepatitis C surveillance in Europe – 2013. Stockholm: ECDC. Available from http://ecdc.europa.eu/en/publications/Publications/hepatitis-c-surveillance-in-europe-2013.pdf. Accessed July 2016. 3. Perlman DC et al. Int J Drug Policy 2015;26:1056–1063.
© 2016 Gilead Sciences Europe Limited HCV/IHQ/16-07//1999 Date of preparation: July 2016
67% OF PEOPLE WHO INJECT DRUGS
HAVE HEPATITIS C, GLOBALLY1
10 MILLIONPEOPLE WHO INJECT
DRUGS IN THE WORLD HAVE HEPATITIS C1
~80% OF NEW HEPATITIS C INFECTIONS RESULT
FROM INJECTION DRUG USE2
~90% OF HEPATITIS C
PATIENTS WHO INJECT DRUGS FAIL TO INITIATE
HEPATITIS C TREATMENT1,3,a
SCREEN DIAGNOSE REFERYou are the first step towards cure
20
VENUE FLOOR PLAN
SCANDINAVIA BALLROOM
Hels
ing
fors
Kø
ben
havn
Sto
ckh
olm
Osl
o
Pos
ters
Ple
nary
Roo
m /
Ses
sion
sSp
eake
r Pre
par
atio
n Roo
m
Exh
ibitio
n
Lunc
h
Holberg Restaurant
INHSU 2016 - Conference Handbook 21
LOCATION MAP
SENTRUM
OSLO
Opera House
Slottsparken
Barcode Project
Posthallen
MSD (Norge) AS, Pb. 458 Brakerøya, 3002 Drammen, tlf. 32 20 73 00, faks 32 20 73 10Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. INFC-1175295-0014 08/16
AN UNWAVERING COMMITMENT TO THE TASK AT HAND
Where a 25-year legacy of innovation in chronic HEPATITIS C treatment1–3 meets
HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES4 According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: It claims the lives of approximately 500,000 people per year.5 However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.
References: 1. PEG-intron and ribavirin combination product approval letter. FDA: August 7, 2001. 2. Victrelis® (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union for treatment of chronic hepatitis C [news release EU version]. Whitehouse Station, NJ: MSD; July 18, 2011. 3. Intron A Registration Life Cycle Status as of January 21, 2011 [FDA]. 4. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed August 4, 2015. 5. World Health Organization. WHO Key Facts. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 11, 2015.
INHSU 2016 - Conference Handbook 23
SOCIAL FUNCTIONS
If you have not confirmed your attendance at any of these events please advise the secretariat at registration urgently for catering purposes.
WELCOME RECEPTIONDate: Wednesday 7 September 2016 Time: 5.00pm - 6.30pm Venue: Foyer, Radisson Blu Scandinavia Hotel
Inclusive in all registrations Guest ticket: ¤50.00
Dress: Smart Casual
CONFERENCE DINNERDate: Thursday 8 September 2016 Time: 7pm - 11pm Venue: Posthallen
Venue details:
� Address: Prinsens gate 8, 0152 Oslo
� Phone: 22:42 82 00
� Fax: 22:42 82 01
� Email: [email protected]
Delegate ticket: ¤100.00 Guest ticket: ¤110.00
Dress: Smart Casual
MSD (Norge) AS, Pb. 458 Brakerøya, 3002 Drammen, tlf. 32 20 73 00, faks 32 20 73 10Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. INFC-1175295-0014 08/16
AN UNWAVERING COMMITMENT TO THE TASK AT HAND
Where a 25-year legacy of innovation in chronic HEPATITIS C treatment1–3 meets
HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES4 According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: It claims the lives of approximately 500,000 people per year.5 However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.
References: 1. PEG-intron and ribavirin combination product approval letter. FDA: August 7, 2001. 2. Victrelis® (boceprevir), first-in-class oral hepatitis C virus protease inhibitor, approved in the European Union for treatment of chronic hepatitis C [news release EU version]. Whitehouse Station, NJ: MSD; July 18, 2011. 3. Intron A Registration Life Cycle Status as of January 21, 2011 [FDA]. 4. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed August 4, 2015. 5. World Health Organization. WHO Key Facts. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed August 11, 2015.
24
INDUSTRY SPONSORED SYMPOSIA
A PRACTICAL APPROACH TO TREATING HCV IN PWIDWhen: Wednesday 7 September, 12.15pm - 1.15pm Where: Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration
Symposium Synopsis: MSD is pleased to present a symposium entitled “A Practical Approach to Treating HCV in PWID.” An internationally renowned faculty chaired by Olav Dalgard will present emerging data on the treatment HCV in PWID. The first lecture by Mojca Maticic will focus on treatment considerations of the PWID including the quality of life of PWIDs, continued drug use, reinfection and barriers to treatment. The second lecture by Ashley Brown will review underlying comorbidities in PWID including an discussion on common co-morbidities such as co-infection, psychiatric conditions and extra-hepatic manifestations in younger vs older PWID, gender differences in co-morbidities and how to manage co-morbidities to ensure a successful treatment.
MAKING HCV ELIMINATION A REALITY FOR PWIDWhen: Thursday 8 September, 12.15pm - 1.15pm Where: Stockholm/Oslo Room, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration
Symposium Synopsis: With HCV cure rates of more than 90%, the direct-acting antiviral agents afford the opportunity to eliminate HCV infection from groups of affected patients. In medium-to-high income countries people who inject drugs are disproportionately affected by HCV. Low HCV treatment uptake among people who inject drugs indicate that these patients come up against many challenges in accessing HCV treatment and care. In this educational symposium the faculty will be focusing on what is being done from a global policy perspective and what needs to be done at a country level to make HCV elimination a reality.
INHSU 2016 - Conference Handbook 25
TREAT TO CURE. TREAT TO PREVENT. Management of Substance Users with HCV Infection
When: Friday 9 September, 12.15pm - 1.15pm Where: Scandinavia Ballroom, Radisson Blu Scandinavia Hotel Cost: Included in your delegate registration
Symposium Synopsis: The past decade has seen unprecedented advances in hepatitis C treatment with new highly effective all-oral interferon-free direct-acting antiviral therapies. Drug users have traditionally been a challenging patient population to treat and can be at risk of reinfection following successful treatment.
This cutting-edge AbbVie-sponsored symposium will cover topics ranging from current treatment options and access to care, to treatment to prevent the spread of hepatitis C in people who use drugs.
We would be delighted to invite you to this symposium with some of the world’s leading experts in the field of viral hepatitis. With the opportunity to pose questions to the panel, this debate-style symposium promises to be an interactive and educational meeting that will address a wide range of issues facing physicians today.
28
EXHIBITION BOOTH LISTING
BOOTH 1Echosens is a pioneer in non-invasive diagnosis solutions in hepatology.
FibroScan®, based on proprietary Vibration Control Transient Elastography ™, is the only worldwide clinically validated medical device using elastography with more than 900 peer-reviewed publications.
FibroMeter® is a range of scores combining several blood biomarkers to measure the degree of fibrosis in the liver.
FibroView™ offers a broad range of smart connectivity solutions linking FibroScan® to the HIS (Hospital Information Systems).
BOOTH 2
Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.
BOOTH 3/4
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.
BOOTH 5/6
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. We demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.
INHSU 2016 - Conference Handbook 29
3/4
7/85/6
21
9
Reception
Hotel Lobby >
BOOTH 7/8
AbbVie is a global biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. Its mission is to develop and market therapies that address some of the world’s most complex and serious diseases. Together with its subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people and markets medicines in more than 170 countries.
BOOTH 9
The International Network on Hepatitis Care in Substance Users (INHSU) is an international organization dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care with people who use drugs.
At Cepheid we are focused on providing fast and actionable results that improve patient outcomes and reduce complications in the most vulnerable populations. Please visit the Cepheid booth to experience how same day, on-demand and ultrasensitive molecular results can impact the HCV epidemic now.
Come visit us at the Cepheid Booth #2
Revolutionizing HCV Management in PWID*
* People Who Inject Drugs
CE-IVD. Not available in all countries.
INHSU 2016 - Conference Handbook 31
NOTES
At Cepheid we are focused on providing fast and actionable results that improve patient outcomes and reduce complications in the most vulnerable populations. Please visit the Cepheid booth to experience how same day, on-demand and ultrasensitive molecular results can impact the HCV epidemic now.
Come visit us at the Cepheid Booth #2
Revolutionizing HCV Management in PWID*
* People Who Inject Drugs
CE-IVD. Not available in all countries.
INHSU 2016 - Conference Handbook 33
INHSU CONFERENCE 2016
THANK YOU TO OUR SPONSORS & SUPPORTERS
Platinum Sponsors
Bronze Sponsor